SOFINNOVA
7.3.2023 10:01:50 CET | Business Wire | Press release
Sofinnova Partners (“Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced that Noema Pharma (“Noema”), has raised an oversubscribed CHF 103 million (approx. USD 112 million) Series B financing round. Sofinnova co-founded and seed financed Noema in 2019 with Dr. George Garibaldi and Luigi Costa. The company was established to advance clinical stage assets in-licensed from Roche.
Noema is a clinical-stage biopharmaceutical company focused on central nervous system disorders. Existing investors Sofinnova Partners, Polaris Partners, Gilde Healthcare and Invus welcomed new investors Forbion and Jeito Capital, as well as UPMC Enterprises and another undisclosed investor.
The proceeds of the Series B financing will be used to advance Noema Pharma's clinical-stage assets, including its lead compound basimglurant (NOE-101), an mGluR5 inhibitor that is being evaluated in Phase 2b clinical trials for severe pain in Trigeminal Neuralgia (TN) and seizures in Tuberous Sclerosis Complex (TSC). The company is also developing gemlopodect (NOE-105), a PDE10a inhibitor being evaluated in Phase 2b clinical trials for Tourette Syndrome and Childhood Onset Fluency Disorder (COFD) or Stuttering; and NOE-115, a Phase 2 ready triple reuptake inhibitor for Atypical Depression and Binge Eating Disorder.
Antoine Papiernik, Chairman and Managing Partner of Sofinnova Partners, said: “As co-founders and initial investors of Noema, we are incredibly proud of what the company has accomplished since its inception. Raising an oversubscribed funding round of this magnitude is a significant achievement that further reinforces our conviction that Noema can make a meaningful difference in the lives of patients suffering from debilitating CNS disorders. Noema is the perfect illustration of our core strategy and expertise: we nurture innovative companies centered on groundbreaking science and exceptional talent that have the potential to deliver transformative results for patients.”
Luigi Costa, Chief Executive Officer of Noema Pharma, said: "We are excited to announce the successful completion of this oversubscribed Series B financing round and very pleased to have a world-class group of investors supporting our vision of bringing much-needed treatments to those living with debilitating central nervous system disorders. This financing comes at a key time for Noema Pharma as we look forward to extensive news flow over the next 24 months.”
The Series B financing follows a CHF 54 million (approx. USD 60 million) Series A financing concluded in December 2020, led by Sofinnova Partners and Polaris Partners. Noema Pharma was founded in 2019 with a seed investment from Sofinnova Partners and four clinical stage assets in-licensed from Roche.
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.
Founded in 1972, Sofinnova Partners is a deeply established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2.5 billion under management. For more information, please visit: sofinnovapartners.com.
About Noema Pharma
Noema Pharma (www.noemapharma.com) is a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders characterized by imbalanced neuronal networks. The Company has a well differentiated pipeline with four mid clinical-stage therapeutic product candidates in-licensed from Roche. Noema currently has 3 active Phase 2b clinical trials in highly undertreated CNS conditions: seizures in Tuberous Sclerosis Complex, severe pain in Trigeminal Neuralgia and Childhood Onset Fluency Disorder. The Company has completed a Phase 2a clinical trial in adult patients with Tourette Syndrome that is currently being extended with an adolescent cohort. The Company has also completed preclinical validation studies in Atypical Depression and Binge Eating Disorder. Noema Pharma was founded in 2019 by the leading venture capital firm Sofinnova Partners. Additional investors include Biomed Partners, Forbion, Gilde Healthcare, Invus, Jeito Capital, Polaris Partners, UPMC Enterprises, and an undisclosed investor.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230307005296/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brightfin Unveils Budget Clarity AI, Giving Every Finance and IT Leader a Financial Analyst at the Tip of Their Fingers29.9.2026 16:18:00 CEST | Press release
New AI capability turns the 101 questions finance teams field every day into self-service answers, letting anyone dig into spend, risk, and budget tradeoffs without waiting on an analyst or learning a new system Brightfin, the leader in technology financial management, today announced Budget Clarity AI, a new capability that gives finance and IT teams instant, self-service answers to the budget questions they field dozens of times a day. Built into the Brightfin platform, Budget Clarity AI acts as an always-available financial analyst, letting users ask plain-language questions about their spend and get grounded answers, visualizations, and recommendations in seconds. Finance and IT leaders are fielding an ever-growing volume of ad-hoc budget questions from stakeholders across the business, while the analysts who could answer them are stretched thin. Budget Clarity AI is designed to close that gap. Users don't need to know ServiceNow, and they don't need to know Brightfin's products —
Laserfiche Names Garrett Boss as CIO to Lead Enterprise IT, Security, and Business Transformation29.9.2026 16:00:00 CEST | Press release
Laserfiche — the leading SaaS provider of intelligent content management and business process automation — today announced the appointment of Garrett Boss as chief information officer. Boss will oversee Laserfiche’s global IT services team and business transformation office, including deployment of internal Laserfiche solutions and all other enterprise-wide IT systems. In this role, he will also oversee governance, risk, and compliance, supporting Laserfiche's mission to scale AI innovation while safeguarding the critical content and lifecycle tools customers rely on. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929335686/en/ Garrett Boss joins Laserfiche as chief information officer. “Laserfiche’s own technology infrastructure and security posture are central to how we deliver an exceptional product and responsive services,” said CEO Karl Chan. “Garrett is a proven leader with a track record of leading global IT and go
CEO Pay Tops $18 Million as Turnover Drives Six-Year High in Sign-On Bonuses, According to Diligent29.9.2026 15:00:00 CEST | Press release
New Diligent Market Intelligence report finds succession costs rising as boards compete for scarce leadership talent and compensation committees face sharper investor scrutiny Median granted CEO pay at S&P 500 companies rose by more than 8% in 2025 to reach $18.2 million, while cash sign-on bonuses for incoming CEOs hit a six-year high, according to the Executive Compensation in 2026 report from Diligent Market Intelligence. The findings point to a more consequential compensation environment for boards: leadership talent is in shorter supply, CEO transitions are costly, and investors continue to scrutinize how pay decisions connect to performance and long-term value. The Russell 3000 also saw remuneration packages grow larger, with median granted CEO pay climbing over 2% to $7.4 million. “This level of growth has been fueled by performance-based equity and stock awards while both indices have been delivering strong total shareholder returns,” said Josh Black, Editor-in-Chief of Diligen
Momentum Grows for Miro MCP as Users Embrace the Canvas for AI Collaboration29.9.2026 15:00:00 CEST | Press release
Calls to Miro’s MCP server surge past 16 million; MCP jumps the developer niche with individuals in non-engineering roles now among the majority embracing the technology Miro®, the collaboration and context layer for the AI era, has reported more than 16 million calls to its MCP server since its launch in February 2026, with usage more than doubling since May. In September alone, MCP calls are on track to reach 6 million*. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929837812/en/ Miro's MCP server is a Model Context Protocol integration letting AI tools connect to Miro boards—creating diagrams, tables, and canvas content, and reading existing board data programmatically. Teams increasingly rely on AI to accelerate work—from discovery and planning to design and code. Yet most AI interactions happen in chat windows or static outputs that exist separately from the team's actual workspace. Miro's MCP server changes this by
NTT DATA Launches ‘Intact, intelligent action.’ to Protect Fragile Places and Advance Sustainability Commitments29.9.2026 15:00:00 CEST | Press release
Global initiative will combine awareness, technology and stewardship to support fragile places around the world. Program will help translate sustainability commitments into practical actions. In the initiative’s first chapter, NTT DATA employees will join Antarctic expedition led by Robert Swan, OBE, on the 40th anniversary of his first South Pole expedition. NTT DATA, a global leader in AI, digital business and technology services, today announced “Intact, intelligent action.” This global initiative is designed to help people and organizations translate sustainability commitments into meaningful action. The effort combines awareness, technology and stewardship in support of some of the world’s most treasured yet fragile places. Antarctica will be the first chapter. From November 25 to December 2, 2026, a dozen NTT DATA employees will join polar explorer Robert Swan and his 2041 Leadership on the Edge expedition aboard the Magellan Explorer. With the Antarctic Peninsula and nearby isla
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom